Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.61 USD

83.61
5,456,718

+0.57 (0.69%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $83.61 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Galapagos (GLPG) Falls on Inflammatory Study Data Readout

Galapagos (GLPG) announces data from multiple studies evaluating its two inflammatory candidates - GLPG3970 and GLPG3667. Stock down.

The Zacks Analyst Blog Highlights: JPMorgan, Intel, McDonald's, CME Group and Gilead Sciences

The Zacks Analyst Blog Highlights: JPMorgan, Intel, McDonald's, CME Group and Gilead Sciences

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $68.22, moving +0.78% from the previous trading session.

Sheraz Mian headshot

Top Stock Reports for JPMorgan, Intel & McDonald's

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), Intel (INTC), and McDonald's (MCD).

Gilead (GILD) Gains 19% YTD: What to Expect in The Second Half?

Gilead (GILD) maintains momentum in the year so far on the back of Veklury for the treatment of COVID-19 and the same is expected to continue in the second half.

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $68.86, moving +1.37% from the previous trading session.

Gilead's (GILD) Kite Announces Positive Data on Yescarta

Gilead (GILD) announces results from the ZUMA-7 study on Yescarta and completes submission of application to the FDA seeking approval of lenacapavir.

Roche's (RHHBY) Actemra Gets FDA Emergency Nod for COVID-19

The FDA issues an Emergency Use Authorization for Roche's (RHHBY) Actemra for the treatment of COVID-19 in hospitalized adults and pediatric patients.

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

Gilead Sciences (GILD) closed at $67.18 in the latest trading session, marking a +0.8% move from the prior day.

Gilead (GILD) Veklury Data Positive in Hospitalized COVID Patients

Gilead (GILD) announces positive data on Veklury in hospitalized patients with COVID-19 across three analyses of large retrospective real-world data sets.

Gilead (GILD) Inks Deal to Develop Allogeneic Cell Therapies

Gilead's (GILD) wholly owned subsidiary Kite signs partnership deal with Shoreline Biosciences to develop novel cell therapies for cancer.

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $67.22, marking a -0.16% move from the previous day.

Neena Mishra headshot

Should You Buy Biotech ETFs Now?

Biotech stocks are rallying this month; can the trend continue?

Cocrystal's (COCP) Antiviral CDI-45205 Effective Against COVID-19

Cocrystal (COCP) SARS-CoV-2 3CL protease inhibitor, CDI-45205, found to be effective in treating the original and two other variants of the COVID-19 virus. Shares up.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed at $68.77 in the latest trading session, marking a -0.75% move from the prior day.

Gilead (GILD) Gets FDA Nod for Label Expansion of Epclusa

Gilead (GILD) obtains FDA approval for the label expansion of HCV drug, Epclusa, to include children as well.

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

Gilead Sciences (GILD) closed at $67.43 in the latest trading session, marking a +1.43% move from the prior day.

Intercept (ICPT) Ocaliva's Prescribing Information Updated

Intercept's (ICPT) PBC drug Ocaliva's label updated due to worsening of liver problems in some patients with cirrhosis.

Zacks Industry Outlook Highlights: Regeneron, Gilead Sciences, Amgen, Biogen, BioNTech, Repligen and Ovid Therapeutics

Zacks Industry Outlook Highlights: Regeneron, Gilead Sciences, Amgen, Biogen, BioNTech, Repligen and Ovid Therapeutics

Ekta Bagri headshot

3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem

The focus on coronavirus treatments should maintain momentum for the volatile Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BNTX, RGEN and OVID to perform well.

Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Beat

Intercept (ICPT) posts a narrower loss for the first quarter. Also, sales surpass expectations. However, Ocaliva's safety label remains a concern.

Sweta Jaiswal, FRM headshot

How Will Biotech ETFs React to These Q1 Earnings Releases?

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

FATE Reports Wider-Than-Expected Q1 Loss, Beats on Revenues

FATE reports a wider Q1 loss on increased R&D expenses.

Ligand (LGND) Q1 Earnings Top, Bad Weather Hits Captisol Sales

Ligand (LGND) reports mixed first-quarter 2021 numbers with earnings beating estimates but revenues missing the same. Stock down.

Gilead (GILD) Beats on Q1 Earnings, HIV Sales Decline

Gilead (GILD) reports mixed results for the first quarter as the ongoing pandemic adversely impacted core HIV segment sales.